SEC Filing Summary: Rexahn Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Rexahn Pharmaceuticals, Inc. on September 15, 2005, reporting events that occurred on September 12, 2005. The filing discloses the entry into material definitive agreements regarding executive employment and changes to non-employee director compensation. Note: The request metadata referenced "Opus Genetics, Inc.," but the source document explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics and Compensation Terms
The filing does not provide revenue, profit, cash flow, or debt metrics. It details the following compensation structures for key personnel effective September 12, 2005:
- CEO (Chang H. Ahn): Annual base salary of $350,000; eligible for an annual cash bonus up to 75% of base salary; eligible for stock options and additional discretionary bonuses.
- CFO (Tae Heum Jeong): Annual base salary of $160,000; eligible for an annual cash bonus up to 50% of base salary; eligible for stock options and additional discretionary bonuses.
- CBO (George Steinfels): Annual base salary of $200,000; eligible for an annual cash bonus up to 50% of base salary; eligible for stock options and additional discretionary bonuses.
- Non-Employee Directors: Granted 20,000 stock options per year of service and a meeting fee of $1,000 per meeting attended.
Material Changes Versus Prior Period
The filing represents a new contractual framework for the named executives and directors. Prior to this date, these specific terms were not in effect. The agreements establish fixed terms (5 years for the CEO, 2 years for the CFO and CBO) after which employment becomes "at-will" unless extended in writing.
Outlook, Risks, and Contingencies
Termination Provisions:
- Without Cause: Executives are entitled to pro-rata bonuses, 6 months of base salary, and 18 months of health insurance coverage upon termination without cause (subject to mitigation and release requirements).
- Change of Control: If terminated without cause within one year of a Change of Control, the CEO receives the greater of the remainder of the agreement term or one year of base salary. The CFO and CBO receive one year of base salary.
- Section 409A: Payments constituting nonqualified deferred compensation for "specified employees" are delayed by six months following separation from service.
Investor Verification Checklist
- Verify the total number of shares reserved in the Stock Option Plan to assess dilution from the 20,000 options granted annually to each non-employee director.
- Review the specific definitions of "Cause" and "Disability" in the attached exhibits (10.1, 10.2, 10.3) to understand the conditions under which severance is forfeited.
- Confirm the company's current cash position to evaluate its ability to fund potential severance packages (up to 1 year of salary for executives in Change of Control scenarios).
- Check for any prior employment agreements to determine if these new terms represent a significant increase in compensation obligations.